J Korean Neurol Assoc.  1988 Dec;6(2):129-138.

Corticosteriod Therapy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

• Lee KW
• Lee SB
• Myung HJ
• Chi JG

Abstract

Since the clinical features were first delineated in 1975 by Dyck et al, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been clearly recognized as a separate clinical entity. The diagnosis of CIDP can be made when there are a symmetrical motor & sensory polyneuropathy with chronic progression, high CSF protein level and marked nerve conduction abnormalities of demyelinating type, which occur in the absence of associated illness. From July 1985 to June 1987, authors have observed seven cases of CIDP. Prednisone was begun at a daily dosage of 1-2mg per kg when each patient fulfilled the above described critera. Significant clinical improvement was recorded in six out of seven cases within four weeks after initiation of corticosteriod therapy. In one case dramatic relief of tingling sensation was observed within 5th day, but motor power improved gradually during the sixth to eighth weeks of daily theapy. No significant side effects of prednisone was found in all cases except for one, who suffered from compressed fracture of lumbar vertebra with minor physical trauma. Therefore it could be concluded that corticosteriod therapy seems to have beneficial effect on patients with severe degree of CIDP.

MeSH Terms

Diagnosis
Humans
Neural Conduction
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*
Prednisone
Sensation
Spine
Prednisone